Related Experiment Videos

Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery

Arthur W Wallace1, Daniel Galindez, Ali Salahieh

  • 1Department of Anesthesia and Perioperative Care, University of California, USA. awallace@cardiacengineering.com

Anesthesiology
|July 28, 2004
PubMed

Insights

Prophylactic clonidine significantly reduces perioperative myocardial ischemia and postoperative death in patients undergoing noncardiac surgery. This cardiac risk reduction strategy offers improved patient outcomes.

Area of Science:

  • Cardiology
  • Anesthesiology
  • Pharmacology

Background:

  • Perioperative myocardial ischemia affects 20-40% of at-risk patients, increasing cardiac morbidity.
  • This condition is linked to a ninefold rise in cardiac morbidity risk.

Purpose of the Study:

  • To evaluate the efficacy of prophylactic clonidine in reducing perioperative myocardial ischemia.
  • To assess the impact of clonidine on postoperative mortality in patients undergoing noncardiac surgery.

Main Methods:

  • A prospective, double-blinded, randomized controlled trial involving 190 patients at risk for coronary artery disease.
  • Patients received either clonidine (n=125) or placebo (n=65) via oral and transdermal routes for 4 days.
  • The study compared the incidence of perioperative myocardial ischemia and 2-year postoperative mortality between groups.

Main Results:

  • Clonidine significantly reduced perioperative myocardial ischemia (14% vs. 31%; P=0.01).
  • Clonidine administration showed minimal hemodynamic effects.
  • A significant reduction in 2-year postoperative mortality was observed with clonidine (15% vs. 29%; P=0.035).

Conclusions:

  • Perioperative administration of clonidine effectively reduces myocardial ischemia in at-risk patients.
  • Clonidine is associated with a significant decrease in postoperative mortality.
  • This prophylactic approach offers a promising strategy for managing cardiac risk in noncardiac surgery.
Abstract

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Cardiac Catheterization IV: Nursing Management01:26

Cardiac Catheterization IV: Nursing Management

Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...